Clinical Trials Browser

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Rectal Neoplasms

Gastric Adenocarcinoma

Muscle Invasive Bladder Cancer (MIBC)

HER2-low Breast Cancer

Breast Neoplasms

Biliary Tract Neoplasms

Breast Neoplasms

Ovarian Neoplasms

Breast Neoplasms

HER2-positive Gastric Cancer

Stomach Neoplasms

Lung Neoplasms

Breast Neoplasms

Stomach Neoplasms

Non-Muscle Invasive Bladder Neoplasms

HER2-positive Gastric Cancer

Castration-resistant Prostate Cancer

Breast Neoplasms

Stomach Neoplasms

Pancreatic Neoplasms

Uterine Cervical Neoplasms

Carcinoma, Non-Small-Cell Lung

Stomach Neoplasms

Colorectal Neoplasms

Muscle Invasive Bladder Carcinoma

Non-Muscle Invasive Bladder Neoplasms

Muscle Invasive Bladder Cancer

Carcinoma, Transitional Cell

Breast Neoplasms

Stomach Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Urinary Bladder Neoplasms

Clinical Trials

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

DTP-HER2

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

DECIDING

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

DAB

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

RCTS

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

DETECT

A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer

Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer

A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer